Dr. Siao-Yi Wang
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Studies Cancer
Studies Recurrence
3 reported clinical trials
6 drugs studied
Area of expertise
1Cancer
Stage IV
PD-L1 positive
p16 positive
2Recurrence
Stage IV
PD-L1 positive
p16 positive
Affiliated Hospitals
Clinical Trials Siao-Yi Wang is currently running
Ipatasertib + Immunotherapy
for Head and Neck Cancer
This trial is testing whether adding a new drug, ipatasertib, to an existing treatment, pembrolizumab, can better treat head and neck cancer that has returned or spread. Ipatasertib may help stop cancer growth, and pembrolizumab helps the immune system attack the cancer. The goal is to see if this combination works better than using pembrolizumab alone. Pembrolizumab has been used in combination with chemotherapy for various cancers, including head and neck cancer, and has shown improved overall survival and response rates.
Recruiting1 award Phase 225 criteria
Relatlimab + Immunotherapy
for Nasopharyngeal Cancer
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.
Recruiting1 award Phase 210 criteria
More about Siao-Yi Wang
Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Siao-Yi Wang has experience with
- Talazoparib
- Atezolizumab
- Ipatasertib
- Pembrolizumab
- Nivolumab
- Relatlimab
Breakdown of trials Siao-Yi Wang has run
Cancer
Recurrence
Small Cell Lung Cancer
Small Cell Carcinoma
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Siao-Yi Wang specialize in?
Siao-Yi Wang focuses on Cancer and Recurrence. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Siao-Yi Wang currently recruiting for clinical trials?
Yes, Siao-Yi Wang is currently recruiting for 2 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Siao-Yi Wang has studied deeply?
Yes, Siao-Yi Wang has studied treatments such as Talazoparib, Atezolizumab, Ipatasertib.
What is the best way to schedule an appointment with Siao-Yi Wang?
Apply for one of the trials that Siao-Yi Wang is conducting.
What is the office address of Siao-Yi Wang?
The office of Siao-Yi Wang is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.